LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

CEL-SCI Corp

Cerrado

SectorSalud

0.22

Resumen

Variación precio

24h

Actual

Mínimo

0.22

Máximo

0.22

Métricas clave

By Trading Economics

Ingresos

-964K

-7.1M

BPA

-0.096

EBITDA

-225K

-5.9M

Dividendos

By Dow Jones

Próximas Ganancias

14 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-23M

21M

Apertura anterior

0.22

Cierre anterior

0.22

Noticias sobre sentimiento de mercado

By Acuity

86%

14%

363 / 382 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

CEL-SCI Corp Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

16 may 2025, 19:39 UTC

Principales Movimientos del Mercado

UroGen Falls to 52-Week Low, FDA Document Indicates Cancer Drug Study Disagreement

17 may 2025, 09:30 UTC

Principales Noticias
Ganancias

In a Trade War, Walmart Lacks Some of Amazon's Ammunition -- Heard on the Street -- WSJ

17 may 2025, 08:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

17 may 2025, 08:20 UTC

Charlas de Mercado
Ganancias

Financial Services Roundup: Market Talk

17 may 2025, 05:30 UTC

Adquisiciones, fusiones, absorciones

Tradeweb Is Looking to Come to a Bond Market Near You -- Barrons.com

16 may 2025, 23:18 UTC

Principales Noticias

U.S. Loses Last Triple-A Credit Rating -- 2nd Update

16 may 2025, 22:30 UTC

Principales Noticias

U.S. Loses Last Triple-A Credit Rating -- Update

16 may 2025, 21:56 UTC

Charlas de Mercado

Fitch Raises Greece's Outlook to Positive From Stable -- Market Talk

16 may 2025, 21:56 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

16 may 2025, 21:54 UTC

Principales Noticias

U.S. Loses Last Triple-A Credit Rating -- WSJ

16 may 2025, 21:22 UTC

Charlas de Mercado

Moody's Says U.S. Fiscal Performance Likely to Deteriorate -- Market Talk

16 may 2025, 21:17 UTC

Charlas de Mercado

Treasury Yields Rise, Dollar Falls After Moody's Cuts U.S. Credit Rating -- Market Talk

16 may 2025, 21:17 UTC

Principales Noticias

The Score: UnitedHealth, Walmart, Coinbase Global and More Stocks That Moved on the Week's News -- WSJ

16 may 2025, 21:05 UTC

Charlas de Mercado

Moody's Downgrades U.S. Credit Rating Due to Deficit, Debts -- Market Talk

16 may 2025, 20:55 UTC

Adquisiciones, fusiones, absorciones

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 may 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Financial Services Roundup: Market Talk

16 may 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

16 may 2025, 20:37 UTC

Principales Noticias

Trade Progress Sparks Bullish Week for Wall Street -- WSJ

16 may 2025, 20:33 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Dick's-Foot Locker Deal Looks Like a Bet on Nike's Turnaround -- Market Talk

16 may 2025, 20:30 UTC

Adquisiciones, fusiones, absorciones

Galaxy Digital Begins U.S. Trading as Bitcoin Keeps Powering Ahead -- Barrons.com

16 may 2025, 20:18 UTC

Principales Noticias

Major U.S. Stock Indexes Rise; U.S. Running Out of Patience for Trade Deals -- WSJ

16 may 2025, 20:16 UTC

Principales Noticias

Justice Department Wants to Spare Boeing From Guilty Plea Over 737 MAX Charges -- 3rd Update

16 may 2025, 20:15 UTC

Ganancias

Tesla Stock Rises. Even Hedge Fund Sales Can't Keep It Down. -- Barrons.com

16 may 2025, 20:11 UTC

Adquisiciones, fusiones, absorciones

Henry Schein: William K. Daniel Joins Board

16 may 2025, 20:10 UTC

Adquisiciones, fusiones, absorciones

Henry Schein: Strategic Investment by KKR Completed

16 may 2025, 20:05 UTC

Adquisiciones, fusiones, absorciones

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 may 2025, 19:38 UTC

Charlas de Mercado

Oil Futures Post Second Straight Weekly Gain -- Market Talk

16 may 2025, 19:07 UTC

Charlas de Mercado

U.S. Natural Gas Futures End Week Lower -- Market Talk

16 may 2025, 18:51 UTC

Principales Noticias

Early Read on Consumer Sentiment Falls to Second Lowest on Record -- 5th Update

16 may 2025, 18:41 UTC

Adquisiciones, fusiones, absorciones

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

Comparación entre iguales

Cambio de precio

CEL-SCI Corp Esperado

Consenso

By TipRanks

0 ratings

0

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

N/A / 0.2494Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

363 / 382 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura bajista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de CEL-SCI Corp

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.